Delivery Order SPE2DB22D2211-SPE2DB25FSCTD
- Not listed
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injector on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $12,888.54 to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order represents a non-set-aside competitive award issued on August 18, 2025. Benlysta (belimumab) is a monoclonal antibody treatment used for systemic lupus erythematosus, a severe autoimmune disease, and its procurement through DLA supports military and federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,076.40 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL syringes. This competitively awarded, firm fixed-price contract was issued on August 12, 2025, with an ultimate completion date of September 3, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $6,152.80 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Benlysta 200 mg/ml syringes. This competitive award, utilizing firm fixed-price contract terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $9,229.20 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml syringes, with an ultimate completion date of August 12, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis, representing a specialized pharmaceutical product within the federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,076.40 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml syringes. The contract, issued on August 11, 2025, carries a firm fixed price and is scheduled for completion by September 2, 2025. This is a competitive award with no set-aside designation, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used primarily to treat...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCTDDelivery Order
The Defense Logistics Agency awarded a $18,458.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Benlysta 200 mg/mL syringes. This is a non-set-aside competitive award with an ultimate completion date of September 3, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic immunosuppressant used primarily in the treatment of systemic lupus erythematosus and other autoimmune conditions, representing a specialized pharmaceutical requirement within the military healthcare supply chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime indefinite delivery vehicle provides comprehensive pharmaceutical and medical supply support to military healthcare programs globally, enabling the Defense Health Agency and other federal healthcare systems to procure a broad range of medications, biologics, and medical devices. AmerisourceBergen's position as a major pharmaceutical distributor and critical federal medical vendor is reflected in its extensive portfolio of competitively awarded contracts across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.5k | 8/12/25 |